Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases.

MLA

Giannini, Valentina, et al. “Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases.” Cancers, vol. 14, no. 1, Jan. 2022. EBSCOhost, https://doi.org/10.3390/cancers14010241.

APA

Giannini, V., Pusceddu, L., Defeudis, A., Nicoletti, G., Cappello, G., Mazzetti, S., Sartore-Bianchi, A., Siena, S., Vanzulli, A., Rizzetto, F., Fenocchio, E., Lazzari, L., Bardelli, A., Marsoni, S., & Regge, D. (2022). Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases. Cancers, 14(1). https://doi.org/10.3390/cancers14010241

Chicago

Giannini, Valentina, Laura Pusceddu, Arianna Defeudis, Giulia Nicoletti, Giovanni Cappello, Simone Mazzetti, Andrea Sartore-Bianchi, et al. 2022. “Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases.” Cancers 14 (1). doi:10.3390/cancers14010241.